These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 36796935)

  • 21. Immunogenicity and safety of a second dose of measles-mumps-rubella-varicella vaccine in healthy children aged 5 to 6 years.
    Vesikari T; Baer M; Willems P
    Pediatr Infect Dis J; 2007 Feb; 26(2):153-8. PubMed ID: 17259879
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Modelling Hospitalisation Ratios for Febrile Convulsions and Severe Varicella Under Combined Measles, Mumps, Rubella, and Varicella (MMRV-Priorix-Tetra™) Compared to Separate MMR + V Vaccination.
    Bauchau V; Van Holle L; Cohen C
    Drug Saf; 2015 Nov; 38(11):1095-102. PubMed ID: 26251259
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combination Measles-Mumps-Rubella-Varicella Vaccine in Healthy Children: A Systematic Review and Meta-analysis of Immunogenicity and Safety.
    Ma SJ; Li X; Xiong YQ; Yao AL; Chen Q
    Medicine (Baltimore); 2015 Nov; 94(44):e1721. PubMed ID: 26554769
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ten-year follow-up on efficacy, immunogenicity and safety of two doses of a combined measles-mumps-rubella-varicella vaccine or one dose of monovalent varicella vaccine: Results from five East European countries.
    Prymula R; Povey M; Brzostek J; Cabrnochova H; Chlibek R; Czajka H; Leviniene G; Man S; Neamtu M; Pazdiora P; Plesca D; Ruzkova R; Stefkovicova M; Usonis V; Verdanova D; Wysocki J; Casabona G; Habib MA
    Vaccine; 2021 May; 39(19):2643-2651. PubMed ID: 33858718
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of Combination Measles-Mumps-Rubella-Varicella Vaccine Introduction in Australia.
    Macartney K; Gidding HF; Trinh L; Wang H; Dey A; Hull B; Orr K; McRae J; Richmond P; Gold M; Crawford N; Kynaston JA; McIntyre P; Wood N;
    JAMA Pediatr; 2017 Oct; 171(10):992-998. PubMed ID: 28806450
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The immunogenicity and safety of a tetravalent measles-mumps-rubella-varicella vaccine when co-administered with conjugated meningococcal C vaccine to healthy children: A phase IIIb, randomized, multi-center study in Italy.
    Durando P; Esposito S; Bona G; Cuccia M; Desole MG; Ferrera G; Gabutti G; Pellegrino A; Salvini F; Henry O; Povey M; Marchetti F
    Vaccine; 2016 Aug; 34(36):4278-84. PubMed ID: 27423382
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Policy statement—Prevention of varicella: update of recommendations for use of quadrivalent and monovalent varicella vaccines in children.
    Committee on Infectious Diseases
    Pediatrics; 2011 Sep; 128(3):630-2. PubMed ID: 21873692
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunogenicity and reactogenicity of a single dose of live attenuated varicella vaccine and a booster dose of measles-mumps-rubella vaccine given concomitantly at 12 years of age.
    Parment PA; Svahn A; Rudén U; Bråkenhielm G; Storsaeter J; Akesson L; Linde A
    Scand J Infect Dis; 2003; 35(10):736-42. PubMed ID: 14606613
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The impact of 2-dose routine measles, mumps, rubella, and varicella vaccination in France on the epidemiology of varicella and zoster using a dynamic model with an empirical contact matrix.
    Ouwens MJ; Littlewood KJ; Sauboin C; Téhard B; Denis F; Boëlle PY; Alain S
    Clin Ther; 2015 Apr; 37(4):816-829.e10. PubMed ID: 25726457
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A new combination vaccine for measles, mumps, rubella and varicella.
    Zareba G
    Drugs Today (Barc); 2006 May; 42(5):321-9. PubMed ID: 16801995
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety of measles, rubella and mumps vaccines in adults: a prospective cohort study.
    Ami N; Eyal N; Asaf B; Chen A; Adi B; Drorit A; Neta P; Hajar D; Stav R; Eli S
    J Travel Med; 2021 Dec; 28(8):. PubMed ID: 34101817
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety and immunogenicity of early vaccination with two doses of tetravalent measles-mumps-rubella-varicella (MMRV) vaccine in healthy children from 9 months of age.
    Goh P; Lim FS; Han HH; Willems P
    Infection; 2007 Oct; 35(5):326-33. PubMed ID: 17710370
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunogenicity and safety of measles-mumps-rubella-varicella (MMRV) vaccine followed by one dose of varicella vaccine in children aged 15 months-2 years or 2-6 years primed with measles-mumps-rubella (MMR) vaccine.
    Gillet Y; Steri GC; Behre U; Arsène JP; Lanse X; Helm K; Esposito S; Meister N; Desole MG; Douha M; Willems P
    Vaccine; 2009 Jan; 27(3):446-53. PubMed ID: 19007835
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Varicella Vaccination Coverage and Possible Factors Influencing Parental Vaccination Decisions in Munich Area 2009-2011 after Introduction of Routine Varicella Vaccination].
    Hagemann C; Seeger K; Krämer A; Liese JG; Streng A
    Gesundheitswesen; 2017 Apr; 79(4):286-295. PubMed ID: 27077319
    [No Abstract]   [Full Text] [Related]  

  • 35. Second dose of measles-mumps-rubella-varicella vaccine (MMRV) and the risk of febrile convulsions.
    Schäfer W; Reinders T; Schink T
    Vaccine; 2022 Mar; 40(14):2168-2172. PubMed ID: 35232594
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost-effectiveness of routine varicella vaccination using the measles, mumps, rubella and varicella vaccine in France: an economic analysis based on a dynamic transmission model for varicella and herpes zoster.
    Littlewood KJ; Ouwens MJ; Sauboin C; Tehard B; Alain S; Denis F
    Clin Ther; 2015 Apr; 37(4):830-841.e7. PubMed ID: 25721380
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunogenicity and safety of intramuscular versus subcutaneous administration of a combined measles, mumps, rubella, and varicella vaccine to children 12 to 18 months of age.
    Haas H; Richard P; Eymin C; Fiquet A; Kuter B; Soubeyrand B
    Hum Vaccin Immunother; 2019; 15(4):778-785. PubMed ID: 30481110
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Vaccination with measles, mumps and rubella vaccine and varicella vaccine: safety, tolerability, immunogenicity, persistence of antibody and duration of protection against varicella in healthy children.
    Shinefield HR; Black SB; Staehle BO; Matthews H; Adelman T; Ensor K; Li S; Chan I; Heyse J; Waters M; Chan CY; Vessey SJ; Kaplan KM; Kuter BJ;
    Pediatr Infect Dis J; 2002 Jun; 21(6):555-61. PubMed ID: 12182381
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Varicella immunogenicity with 1- and 2-dose regimens of measles-mumps-rubella-varicella vaccine.
    Shinefield HR; Black S; Kuter BJ
    J Infect Dis; 2008 Mar; 197 Suppl 2():S152-5. PubMed ID: 18419390
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The combination measles, mumps, rubella and varicella vaccine in healthy children.
    Arbeter AM; Baker L; Starr SE; Plotkin SA
    Dev Biol Stand; 1986; 65():89-93. PubMed ID: 3030864
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.